409 related articles for article (PubMed ID: 17587882)
41. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
Abdelhameed A; Pond GR; Mitsakakis N; Brandwein J; Chun K; Gupta V; Kamel-Reid S; Lipton JH; Minden MD; Schimmer A; Schuh A; Yee K; Messner HA
Cancer; 2008 Apr; 112(7):1513-21. PubMed ID: 18286528
[TBL] [Abstract][Full Text] [Related]
42. Bone marrow biopsies in patients 85 years or older.
Manion EM; Rosenthal NS
Am J Clin Pathol; 2008 Nov; 130(5):832-5. PubMed ID: 18854278
[TBL] [Abstract][Full Text] [Related]
43. [Bone-marrow biopsy in chronic myeloid leukemia. Value of the initial examination].
Devred C; Bentata J; Diebold J; Bernadou A; Bilski-Pasquier G
Sem Hop; 1977 Jan; 53(2):119-24. PubMed ID: 189424
[TBL] [Abstract][Full Text] [Related]
44. Evolution of secondary hematologic disorders: preMDS-->MDS-->sAML.
Preisler HD
Cancer Treat Res; 2001; 108():185-230. PubMed ID: 11702600
[No Abstract] [Full Text] [Related]
45. Bone marrow histopathology in myeloproliferative disorders--current diagnostic approach.
Thiele J; Kvasnicka HM; Orazi A
Semin Hematol; 2005 Oct; 42(4):184-95. PubMed ID: 16210032
[TBL] [Abstract][Full Text] [Related]
46. [How extensive are the present indications for bone marrow transplantation?].
Gmür J
Schweiz Med Wochenschr; 1985 May; 115(21):738-43. PubMed ID: 3892662
[TBL] [Abstract][Full Text] [Related]
47. [Pure red-cell aplasia associated with chronic myeloproliferative syndromes].
Villarrubia J; Pascual C; Pérez Vaquero MA; Escribano L; Bellas C; Orte J; Heinrichs B; Velasco JL
Med Clin (Barc); 1992 Feb; 98(4):139-41. PubMed ID: 1552765
[TBL] [Abstract][Full Text] [Related]
48. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.
Kvasnicka HM; Thiele J
Pathobiology; 2007; 74(2):63-71. PubMed ID: 17587877
[TBL] [Abstract][Full Text] [Related]
49. Therapy-related acute leukemia.
Karp JE; Sarkodee-Adoo CB
Clin Lab Med; 2000 Mar; 20(1):71-81, ix. PubMed ID: 10702897
[TBL] [Abstract][Full Text] [Related]
50. Risk assessment in haematopoietic stem cell transplantation.
Gratwohl A
Best Pract Res Clin Haematol; 2007 Jun; 20(2):119-24. PubMed ID: 17448952
[No Abstract] [Full Text] [Related]
51. Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT.
Ditschkowski M; Haferlach C; Schulte C; Trenschel R; Beelen DW
Bone Marrow Transplant; 2009 Aug; 44(4):265-6. PubMed ID: 19234516
[No Abstract] [Full Text] [Related]
52. Chronic myelogenous leukemia: a review and update of therapeutic strategies.
Garcia-Manero G; Faderl S; O'Brien S; Cortes J; Talpaz M; Kantarjian HM
Cancer; 2003 Aug; 98(3):437-57. PubMed ID: 12879460
[No Abstract] [Full Text] [Related]
53. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands.
Dinmohamed AG; van Norden Y; Visser O; Posthuma EF; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M
Leuk Res; 2015 Feb; 39(2):177-82. PubMed ID: 25533930
[TBL] [Abstract][Full Text] [Related]
54. Role of C-kit receptor in the diagnosis of leukemia: a relationship between expression of C-kit receptor and that of CD33 in leukemic blasts.
Muroi K; Amemiya Y; Miura Y; Nakamura M; Suda T
Leuk Res; 1993 Aug; 17(8):725-6. PubMed ID: 7689130
[No Abstract] [Full Text] [Related]
55. Reticulated platelets as a marker of platelet recovery after allogeneic stem cell transplantation.
Michur H; Maślanka K; Szczepiński A; Mariańska B
Int J Lab Hematol; 2008 Dec; 30(6):519-25. PubMed ID: 18983304
[TBL] [Abstract][Full Text] [Related]
56. Ph-positive and -negative myeloproliferative syndromes may co-exist.
Mauro MJ; Loriaux M; Deininger MW
Leukemia; 2004 Jul; 18(7):1305-7. PubMed ID: 15103389
[No Abstract] [Full Text] [Related]
57. [Weakness, bone pain].
Baumeister B; Buck F; Vetter H
Schweiz Rundsch Med Prax; 1990 Jun; 79(23):737-9. PubMed ID: 2367765
[TBL] [Abstract][Full Text] [Related]
58. The burden and outcomes associated with four leukemias: AML, ALL, CLL and CML.
Redaelli A; Stephens JM; Laskin BL; Pashos CL; Botteman MF
Expert Rev Anticancer Ther; 2003 Jun; 3(3):311-29. PubMed ID: 12820775
[TBL] [Abstract][Full Text] [Related]
59. Auer rods in myeloid neoplasms.
Anand M; Ghara N; Singh S; Kumar R
Indian J Pathol Microbiol; 2005 Jan; 48(1):53-4. PubMed ID: 16758792
[No Abstract] [Full Text] [Related]
60. Sequential quantitative MR analysis of bone marrow: differences during treatment of lymphoid versus myeloid leukemia.
Vande Berg BC; Michaux L; Scheiff JM; Malghem J; Lecouvet FE; Bourgois MP; Ferrant A; Michaux JL; Maldague BE
Radiology; 1996 Nov; 201(2):519-23. PubMed ID: 8888252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
